Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONW NASDAQ:AIMDW NASDAQ:SCLXW NASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONWAclarion$0.03-9.2%$0.03$0.02▼$0.23N/AN/A13,262 shs11,345 shsAIMDWAinos$0.12-18.0%$0.10$0.05▼$0.95N/AN/A6,363 shs1,015 shsSCLXWScilex$0.18+2.9%$0.14$0.05▼$0.65N/AN/A5,688 shs575 shsSXTPW60 Degrees Pharmaceuticals$0.04-2.6%$0.05$0.03▼$0.16N/AN/A11,787 shs118 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONWAclarion+0.76%-5.34%-18.40%-35.59%-26.72%AIMDWAinos+31.71%+52.83%+67.36%+80.00%+42.11%SCLXWScilex-5.00%+6.29%-1.87%+12.43%+62.57%SXTPW60 Degrees Pharmaceuticals0.00%-0.26%-15.35%-15.16%-25.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONWAclarion$0.03-9.2%$0.03$0.02▼$0.23N/AN/A13,262 shs11,345 shsAIMDWAinos$0.12-18.0%$0.10$0.05▼$0.95N/AN/A6,363 shs1,015 shsSCLXWScilex$0.18+2.9%$0.14$0.05▼$0.65N/AN/A5,688 shs575 shsSXTPW60 Degrees Pharmaceuticals$0.04-2.6%$0.05$0.03▼$0.16N/AN/A11,787 shs118 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONWAclarion+0.76%-5.34%-18.40%-35.59%-26.72%AIMDWAinos+31.71%+52.83%+67.36%+80.00%+42.11%SCLXWScilex-5.00%+6.29%-1.87%+12.43%+62.57%SXTPW60 Degrees Pharmaceuticals0.00%-0.26%-15.35%-15.16%-25.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONWAclarion 0.00N/AN/AN/AAIMDWAinos 0.00N/AN/AN/ASCLXWScilex 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONWAclarion$77.88KN/AN/AN/AN/AN/AAIMDWAinos$18.11KN/AN/AN/AN/AN/ASCLXWScilex$33.86MN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONWAclarionN/AN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)AIMDWAinosN/AN/AN/AN/AN/AN/AN/AN/AN/ASCLXWScilexN/AN/AN/AN/AN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACONWAclarionN/AN/AN/AN/AN/AAIMDWAinosN/AN/AN/AN/AN/ASCLXWScilexN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONWAclarionN/AAIMDWAinosN/ASCLXWScilexN/ASXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACONWAclarionN/AAIMDWAinosN/ASCLXWScilexN/ASXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONWAclarion7N/AN/ANot OptionableAIMDWAinos40N/AN/ANot OptionableSCLXWScilex105N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableSCLXW, SXTPW, ACONW, and AIMDW HeadlinesRecent News About These Companies60 Degrees details tafenoquine priority review voucher strategyJune 3, 2026 | tipranks.com60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria PreventionApril 15, 2026 | quiverquant.comQ60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational DevelopmentsMarch 31, 2026 | quiverquant.comQ60 Degrees Updates Affiliate Share Ownership Disclosure ErrorMarch 20, 2026 | tipranks.com60 Degrees Pharmaceuticals Updates Legal Opinion for ATM OfferingMarch 13, 2026 | tipranks.com60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance StatusFebruary 12, 2026 | tipranks.comGoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria PreventionFebruary 2, 2026 | quiverquant.comQ60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting AppealJanuary 23, 2026 | tipranks.com60 Degrees Pharmaceuticals Implements One-for-Four Reverse SplitJanuary 21, 2026 | tipranks.com60 Degrees Pharma outlines growth strategy in investor webinarJanuary 8, 2026 | tipranks.com60 Degrees Pharmaceuticals, Inc. Confirms Continuation of B-FREE Study to Assess ARAKODA® for Chronic Babesiosis TreatmentDecember 29, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Plans Expansion of Sales and Marketing Initiatives Following Positive Clinical Pilot ResultsDecember 11, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Launches First-Ever Study for Tafenoquine in Chronic Babesiosis PatientsNovember 21, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth EffortsNovember 17, 2025 | tipranks.com60 Degrees Pharmaceuticals, Inc. Reports 223% Increase in Q3 2025 Net Product Revenue Despite Gross LossNovember 13, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic BabesiosisOctober 27, 2025 | tipranks.com60 Degrees Pharmaceuticals Submits Breakthrough Therapy Designation Request to FDA for Tafenoquine in Treating Relapsing BabesiosisOctober 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals unveils name of chronic babesiosis trialOctober 9, 2025 | msn.com60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyOctober 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Launches B-FREE Chronic Babesiosis Study Following Patient Naming Competition and $5K Charity DonationOctober 9, 2025 | quiverquant.comQMedia Sentiment Over TimeSCLXW, SXTPW, ACONW, and AIMDW Company DescriptionsAclarion NASDAQ:ACONW$0.03 0.00 (-9.25%) As of 03:37 PM Eastern This is a fair market value price provided by Massive. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Ainos NASDAQ:AIMDW$0.12 -0.03 (-18.00%) As of 03:29 PM Eastern This is a fair market value price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Scilex NASDAQ:SCLXW$0.18 +0.01 (+2.94%) As of 03:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.04 0.00 (-2.59%) As of 03:20 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
